Abstract

BackgroundTo evaluate the impact of external beam radiation therapy (XRT) on weekly ultrasound determined post-void residual (PVR) urine volumes in patients with prostate cancer.Methods125 patients received XRT for clinically localized prostate cancer. XRT was delivered to the prostate only (n = 66) or if the risk of lymph node involvement was greater than 10% to the whole pelvis followed by a prostate boost (n = 59). All patients were irradiated in the prone position in a custom hip-fix mobilization device with an empty bladder and rectum. PVR was obtained at baseline and weekly. Multiple clinical and treatment parameters were evaluated as predictors for weekly PVR changes.ResultsThe mean patient age was 73.9 years with a mean pre-treatment prostate volume of 53.3 cc, a mean IPSS of 11.3 and a mean baseline PVR of 57.6 cc. During treatment, PVR decreased from baseline in both cohorts with the absolute difference within the limits of accuracy of the bladder scanner. Alpha-blockers did not predict for a lower PVR during treatment. There was no significant difference in mean PVR urine volumes or differences from baseline in either the prostate only or pelvic radiation groups (p = 0.664 and p = 0.458, respectively). Patients with a larger baseline PVR (>40 cc) had a greater reduction in PVR, although the greatest reduction was seen between weeks one and three. Patients with a small PVR (<40 cc) had no demonstrable change throughout treatment.ConclusionProstate XRT results in clinically insignificant changes in weekly PVR volumes, suggesting that radiation induced bladder irritation does not substantially influence bladder residual urine volumes.

Highlights

  • Sophisticated conformal radiotherapy delivery technologies and organ localization protocols have resulted in significant changes in treatment paradigms offered to patients with clinically localized prostate cancer

  • One hundred and twenty five patients were treated for clinical stage T1b-T3a (2002 AJCC) prostate cancer with either definitive external beam radiation therapy to the prostate only (n = 68) or to the whole pelvis followed by a prostate boost (n = 59) [19]

  • No statistical differences were demonstrated between the groups concerning patient age at treatment, prostate volume, post-void residual urine (PVR) volumes and the use of alpha-blockers during treatment

Read more

Summary

Introduction

Sophisticated conformal radiotherapy delivery technologies and organ localization protocols have resulted in significant changes in treatment paradigms offered to patients with clinically localized prostate cancer. These technologies allow physicians to offer dose escalations to the targets while respecting normal tissue tolerances of surrounding organs [1,2,3,4]. Cone beam CT has been integrated into linear accelerator systems, most CT studies are performed in a manner simulating treatment For this reason, many institutions implant intraprostatic gold fiducial markers for identification on electronic portal imaging. To evaluate the impact of external beam radiation therapy (XRT) on weekly ultrasound determined post-void residual (PVR) urine volumes in patients with prostate cancer

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call